Skip to main content

Table 1 Analysis of S100A2 protein expression and correlation with clinicopathological parameters

From: Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients

Clinicopathological

Test set

External validation set

Features

N

Cytoplasmic

Nuclear

p

N

Cytoplasmic

Nuclear

p

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Normal

129

1.29 (0.99)

1.07 (1.29)

 

51

2.55 (0.88)

2.64 (1.05)

 

OSCC

235

3.04 (1.26)

0.75 (1.03)

<0.00011

115

2.72 (1.06)

2.18 (1.13)

0.051

0.022

0.042

Age (Median, 49 years)

        

<49

115

2.97 (1.31)

0.75 (1.02)

0.401

17

3.12 (1.17)

2.50 (1.17)

0.051

≥49

120

3.12 (1.20)

0.75 (1.05)

0.862

98

2.70 (1.01)

2.17 (1.12)

0.222

Gender

        

Male

184

3.05 (1.26)

0.73 (1.01)

0.651

68

2.74 (1.03)

2.24 (1.10)

0.681

Female

51

3.00 (1.26)

0.80 (1.11)

0.902

47

2.81 (1.06)

2.18 (1.17)

0.732

Differentiation

        

WDSCC

115

3.08 (1.27)

0.81 (1.08)

 

28

2.82 (1.06)

2.54 (1.10)

 

MDSCC

113

2.97 (1.27)

0.70 (0.99)

0.461

70

2.86 (0.92)

2.22 (1.08)

0.281

PDSCC

7

3.57 (0.53)

0.57 (0.98)

0.732

17

2.29 (1.36)

1.68 (1.24)

0.062

Clinical stage

        

I

3

2.67 (2.31)

0.67 (1.15)

 

30

2.70 (1.29)

2.32 (1.26)

 

II

38

2.79 (1.26)

0.79 (1.17)

 

21

2.81 (0.75)

2.48 (1.12)

 

III

69

3.12 (1.18)

0.65 (0.87)

0.361

21

2.52 (1.03)

1.67 (0.91)

0.601

IV

125

3.09 (1.28)

0.79 (1.08)

0.942

43

2.91 (0.97)

2.29 (1.07)

0.092

Tumor stage

        

I

6

2.67 (1.51)

1.17 (1.33)

 

48

2.77 (1.17)

2.25 (1.18)

 

II

69

2.84 (1.26)

0.81 (1.07)

 

38

2.53 (0.95)

2.04 (1.22)

 

III

65

3.20 (1.19)

0.65 (0.89)

0.141

18

3.06 (0.80)

2.28 (0.89)

0.081

IV

95

3.11 (1.28)

0.75 (1.08)

0.712

10

3.30 (0.67)

2.75 (0.72)

0.372

Nodal status

        

N0

81

2.86 (1.43)

0.68 (0.99)

0.321

63

2.78 (1.04)

2.35 (1.11)

0.881

N1–4

154

3.14 (1.15)

0.79 (1.06)

0.462

52

2.75 (1.05)

2.06 (1.13)

0.212

Recurrence status 3

        

Non-recurrent

82

2.60 (1.39)

0.80 (1.04)

<0.011

47

2.60 (0.92)

2.23 (1.14)

0.051

Recurrent

80

3.30 (1.07)

0.89 (1.13)

0.802

55

2.91 (1.11)

2.16 (1.10)

0.792

  1. 1p of Kruskal-Wallis rank sum test on cytoplasmic S100A2 % positivity score; 2p of Kruskal-Wallis rank sum test on nuclear S100A2 % positivity score; 3Only for OSCC cases with follow up information.